YUNNAN BAIYAO(SZ:000538)2025-05-19 09:38Financial Performance - In 2024, the company achieved a revenue of CNY 40.033 billion, a year-on-year increase of 2.36% [2] - The net profit attributable to shareholders reached CNY 4.749 billion, up 16.02% from CNY 4.094 billion in the previous year [2] - The net profit excluding non-recurring items was CNY 4.523 billion, reflecting a 20.18% increase from CNY 3.764 billion [2] - Operating cash flow net amount was CNY 4.297 billion, a growth of 22.68% [3] - The weighted average return on equity was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share were CNY 2.66, up 16.16% [3] Dividend Distribution - The company proposed a cash dividend of CNY 11.85 per 10 shares (tax included) based on a total share capital of 1,784,262,603 shares [4] - A special dividend of CNY 12.13 per 10 shares was completed in November 2024, totaling CNY 2.164 billion [4] - The total cash dividend for 2024, including the special dividend, amounts to CNY 23.98 per 10 shares, totaling CNY 4.279 billion, which is 90.09% of the net profit attributable to shareholders [4] Business Strategy - The company focuses on both "internal" and "external" growth strategies, emphasizing strategic mergers and collaborations to enhance its industry portfolio [6] - The aim is to overcome growth bottlenecks and build a sustainable industry portfolio for high-quality development [6] Research and Development - The company is committed to developing both traditional Chinese medicine and innovative drugs, establishing a comprehensive research system for traditional medicinal resources [7] - It aims to create competitive innovative drugs aligned with national and local biopharmaceutical strategies [7] - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with positive results reported in November [8] - The INR102 injection for prostate cancer treatment has also received approval for clinical trials [9]